# US 2025/0367123 A1 · Pulsatile drug delivery system for treating morning akinesia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367123 A1
- Document ID: US20250367123A1
- Status: Published application
- Kind: A1
- Application number: 19/299,911
- Filed: 2025-08-14
- Published: 2025-12-04
- Earliest claimed: 2022-09-07
- Assignees: Contera Pharma A/S
- Applicants: Contera Pharma A/S
- Inventors: John Bondo HANSEN; Mikael Søndergård THOMSEN; Ann FULLERTON; Bent HØJGAARD; Peter Gudmund NIELSEN
- Web page: https://patentgrep.com/patent/US20250367123A1

## CPC

- A61K 9/2081: {with microcapsules or coated microparticles according to A61K9/50}
- A61K 9/1652: {Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin (homeopathic globules A61K9/1623)}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2059: {Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin}
- A61K 9/2077: {Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets}
- A61K 9/2086: {Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat (active cores with a complete drug-free outer coat A61K9/28)}
- A61K 9/2866: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/4808: {characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release (capsules filled with granules or microparticles A61K9/16; filled with microcapsules or coated microparticles A61K9/50; with mixture of different granules, microcapsules, (coated) microparticles A61K9/5084)}
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/194: having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A61K 31/195: having an amino group
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/16: Anti-Parkinson drugs
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herewith is a pharmaceutical composition comprising, separately or together, a pulsatile release component comprising levodopa and a DOPA decarboxylase inhibitor for the management of OFF-time episodes in patients with Parkinson's disease.

## Claims

### Claim 1

A method of treating a motor symptom in a patient in need of treatment thereof comprising orally administering to the patient, 0 to 4 hours prior to bedtime, a pharmaceutical composition consisting of
an amount of levodopa sufficient for treating the motor symptom;
an amount of a DOPA decarboxylase inhibitor; and
one or more excipients; wherein
the amount of levodopa sufficient for treating the motor symptom is released from the pharmaceutical composition in one pulsatile release, after a levodopa lag time of at least 3 hours after the oral administration;
the amount of the DOPA decarboxylase inhibitor is released form the pharmaceutical composition in one pulsatile release after a DOPA decarboxylase inhibitor lag time of at least 3 hours after the oral administration,
wherein the pharmaceutical composition does not include an amount of controlled release levodopa and wherein the pharmaceutical composition does not include an amount of immediate-release levodopa.

### Claim 2 (depends on 1)

The method of claim 1, wherein the amount of the levodopa in the pharmaceutical composition is 1 mg to 1000 mg.

### Claim 3 (depends on 1)

The method of claim 1, wherein the amount of the levodopa in the pharmaceutical composition is 50 mg to 300 mg.

### Claim 4 (depends on 1)

The method of claim 1, wherein the amount of the DOPA decarboxylase inhibitor in the pharmaceutical composition is 1 mg to 250 mg.

### Claim 5 (depends on 1)

The method of claim 1, wherein the amount of the DOPA decarboxylase inhibitor in the pharmaceutical composition is 10 mg to 75 mg.

### Claim 6 (depends on 1)

The method of claim 1, wherein the DOPA decarboxylase inhibitor is carbidopa, benserazide, methyldopa, or α-difluoromethyl-DOPA (DFMD), or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

The method of claim 1, wherein the DOPA decarboxylase inhibitor is carbidopa.

### Claim 8 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is administered to the patient 0 to 3 hours prior to bedtime.

### Claim 9 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is administered 0 to 1 hours prior to bedtime.

### Claim 10 (depends on 1)

The method of claim 1, wherein the levodopa lag time and the DOPA decarboxylase inhibitor lag time is 3 to 7 hours after the oral administration.

### Claim 11 (depends on 1)

The method of claim 1, wherein the levodopa lag time and the DOPA decarboxylase inhibitor lag time is about 4 hours after the oral administration.

### Claim 12 (depends on 1)

The method of claim 1, wherein the levodopa lag time and the DOPA decarboxylase inhibitor lag time is about 6 hours after the oral administration.

### Claim 13 (depends on 1)

The method of claim 1, wherein in said pulsatile release 70 to 100% of the amount of the levodopa is released from the pharmaceutical composition within 2 hours after the levodopa lag time, and 70 to 100% of the amount of the DOPA decarboxylase inhibitor is released from the pharmaceutical composition within 2 hours after the DOPA decarboxylase inhibitor lag time.

### Claim 14 (depends on 1)

The method of claim 1, wherein the levodopa lag time is longer than the DOPA decarboxylase inhibitor lag time.

### Claim 15 (depends on 14)

The method of claim 14, wherein the levodopa lag time is 3 to 7 hours after the oral administration and the DOPA decarboxylase inhibitor lag time is 3 to 6 hours after the oral administration.

### Claim 16 (depends on 14)

The method of claim 14, wherein the levodopa lag time is about 4 to 7 hours after the oral administration and the DOPA decarboxylase inhibitor lag time is 3 to 6 hours after the oral administration.

### Claim 17 (depends on 1)

The method of claim 1, wherein said patient in need of treatment is a patient with Parkinson's disease.

### Claim 18 (depends on 1)

The method of claim 1, wherein the motor symptom is a symptom of morning akinesia.

### Claim 19 (depends on 1)

The method of claim 1, wherein the motor symptom comprises tremor, slowness, muscle stiffness, freezing and falls, or difficulty in moving and walking in the morning.
